NAD<sup>+</sup>-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin
Dongjie Li, Si-Jia Sun, Jiang‐Tao Fu, Shen‐Xi Ouyang, Qin-Jie Zhao, Li Su, Qing-Xi Ji, Di-Ynag Sun, Jiahui Zhu, Guo‐Yan Zhang, Jiawei Ma, Xiu-Ting Lan, Yi Zhao, Jie Tong, Guoqiang Li, Fu‐Ming Shen, Pei Wang
Abstract
-boosting therapy in metabolic pathophysiology.
Topics & Concepts
Nonalcoholic fatty liver diseaseBoosting (machine learning)NAD+ kinaseMedicineNonalcoholic steatohepatitisFNDC5DiseaseInternal medicineEndocrinologyCancer researchBioinformaticsFatty liverChemistryComputer scienceBiologyBiochemistryArtificial intelligenceEnzymeCellFibronectinAdipose Tissue and MetabolismMitochondrial Function and PathologyLiver Disease Diagnosis and Treatment